SonoThera
Sandra Rivas, MSc, RAC, currently serves as Vice President and Head of Regulatory Affairs at SonoThera since March 2025. Additionally, Sandra has been the President of RCG Real Estate Holdings, LLC since 2012, focusing on real estate investing. Prior experience includes senior regulatory roles at Sarepta Therapeutics, where Sandra was Senior Director of Regulatory Affairs for Gene Therapy, and BeiGene, where Sandra served as Director of Regulatory Affairs in Oncology. Expertise in regulatory strategy development and project management is evident from a career that includes positions at Precision For Medicine, Halloran Consulting Group, Ultragenyx Pharmaceutical, Allergan, Arena Pharmaceuticals, and Newport Scientific. Sandra's educational credentials include a Master's in Clinical Science from UC San Diego, a Certificate in Advanced Biosciences from UC Berkeley, and a BS in Biochemistry from California State University-Los Angeles, complemented by executive education from Harvard Business School.
This person is not in any teams
This person is not in any offices
SonoThera
SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease.SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people.